#Cancer Biomarker Market
Text
ancer biomarkers encompass a diverse array of molecules, genes, proteins, or other substances that indicate the presence of cancer or its progression. They offer valuable insights into the biological processes underlying cancer development, enabling early detection and targeted interventions. Biomarkers hold immense potential for revolutionizing cancer care by facilitating precision medicine approaches tailored to individual patients.
0 notes
Text
Liquid Biopsy: Evolving Trends in Breast Cancer
The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth. With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment.
Breast Cancer Liquid Biopsy Market Report Highlights
In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer
The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment
Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection
Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population
Gain deeper insights on the market and receive your free copy with TOC now @: Breast Cancer Liquid Biopsy Market Report
There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.
A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.
#Breast Cancer#Liquid Biopsy#Cancer Detection#Biomarkers#Medical Diagnosis#Precision Medicine#Cancer Screening#Tumor Markers#Molecular Diagnostics#Healthcare Technology#Cancer Research#Liquid Biopsy Market#Oncology#Personalized Medicine#Biotechnology
0 notes
Text
Cancer Biomarkers Market
#Cancer Biomarkers Market#Cancer Biomarkers Market Insights#Coherent Market Insights#Cancer Biomarkers Market Analysis#Cancer Biomarkers Market Size#Cancer Biomarkers Market Growth#Cancer Biomarkers Market Trends#oncology#diagnose#cancer#blood#bodily fluids#treatment
0 notes
Text
Europe Cancer Biomarkers Market
Europe Canc Biomarkers Market
0 notes
Text
Global Cancer Biomarkers Market: An Effective Tool Driving Better Cancer Diagnosis, Treatment, and Prognosis
Cancer biomarkers are biological molecules that indicate the existence of cancer in a patient. They are formed either by the cancer cells or by noncancer cells in response to cancer.
The Global Cancer Biomarkers Market is set to witness a growth rate of 6-7% in the next 5 years. Some of the main factors propelling the global cancer biomarkers market include the increasing use of cancer biomarkers in drug discovery and development, favorable funding related to cancer biomarkers, rising research on cancer biomarkers, technological advancements in the development of cancer biomarkers, and the increasing global burden of cancer.
Usage of Cancer Biomarkers Across Different Stages of Cancer Fuels the Cancer Biomarkers Market Demand
Cancer biomarkers are essential for correctly diagnosing and treating cancer at various stages. They are utilized for cancer risk assessment, screening, differential diagnosis, prognosis determination, treatment response prediction, pharmacokinetics/predicting drug doses, and monitoring treatment response. Clinical use of biomarkers for various types of cancer - breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, colon cancer germ cell cancer, and thyroid cancer, amongst others drives its demand.
Increasing Prominence of Cancer Biomarkers in Drug Discovery, Development, and Approval Processes
At every stage of drug discovery and development, biomarkers are being used more and more. The use of biomarkers makes the drug discovery, development, and approval processes more efficient. For the effective treatment of complex chronic diseases (such as cancer), to develop precision medicine and targeted therapies, it is critical to track the molecular basis of disease initiation and development before, during, and after the therapeutic intervention. The necessity to better understand the factors affecting response to drugs has led to an increased demand for additional efficacy, specificity, and safety testing of drugs during new drug development which in turn has bolstered the demand for cancer biomarkers.
Explore Premium Report on Cancer Biomarkers Market @ https://meditechinsights.com/cancer-biomarkers-market/
Favorable Funding Environment Set to Drive the Cancer Biomarkers Market
Organizations across the globe are providing funds/grants to identify cancer biomarkers that can treat diseases with unmet needs in order to reduce the burden of cancer.
For instance,
Cancer Research UK is offering to fund researchers interested in ‘Biomarker Research’. Through their funding scheme ‘Biomarker Project Awards’, Cancer Research UK is offering 3-year funding of up to £100,000 per year for biomarker assay development, validation, and qualification where there is a clear line of sight to clinical implementation
Similarly, the National Institutes of Health (NIH) - Cancer Biomarkers Research Group is offering several funding opportunities for cancer biomarkers
“Cancer biomarker testing is revolutionizing cancer treatment for several types of tumors. The moment we identify a key biomarker and figure out what is driving tumor growth, we can develop treatment strategies that particularly target the tumor abnormality and eventually improve patient outcomes.” - Director, Leading Cancer Center, United States
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold
The cancer biomarkers market is a developing market noticeable by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as new product/program launches, partnerships, and acquisitions to garner market share.
For instance,
In March 2022, Vela Diagnostics launched new panels to detect cancer biomarkers
In March 2022, SYNLAB partnered with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany
Future Outlook of Cancer Biomarkers Market
The cancer biomarkers market is a promising market that is anticipated to gain further momentum in the coming years due to technical progressions in genomic and proteomic technologies (gene array technology, improved two-dimensional gel electrophoresis, new mass spectrometric techniques) and bioinformatic tools that showcase the potential to meet the growing demand for new biomarkers that are both sensitive and specific.
The demand for prognostic and predictive cancer biomarkers is anticipated to rise in order to ensure adequate evaluation and better clinical cancer management. With the growing development of new treatments, there is an increasing requirement for biomarkers that can predict outcomes and direct patients/providers on which treatment options that are most likely to be successful for a specific patient with a particular tumor.
Competitive Landscape Analysis of Cancer Biomarkers Market
The global cancer biomarkers market is marked by the presence of prominent players such as Roche, Thermo Fisher Scientific, QIAGEN, Illumina, Bio-Rad Laboratories, Abbott Laboratories, Sysmex, and others. The foray of players such as R&D Systems, BioVision, Olink, Meso Scale Diagnostics, and others are changing the dynamics of the market and have made the market more competitive.
For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
0 notes
Photo
https://www.databridgemarketresearch.com/reports/global-cancer-biomarkers-market
0 notes
Text
Cancer Biomarkers Market - Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2022 - 2027
Cancer Biomarkers Market size is estimated to reach $25.2 billion by 2027, growing at a CAGR of 11.7% during the forecast period 2022-2027. Biomarkers fall under the category of biological molecules or genes which have their presence in blood and other body fluids. These naturally occurring characteristics are discovered using bioinformatics and play a significant role in finding and understanding diseases and their behaviors. For example, blood pressure, platelets count are biomarkers as they help in the diagnosis of leukemia. Moreover, predictive, and prognostic biomarkers assist doctors in the prescription of personalized medicines to patients which means patients don’t have to go through gratuitous treatments and medications. The cancer biomarkers market outlook is exceptionally enchanting as the prevalence of various types of cancer has heightened in recent years. Rapid growth in biomarkers-associated technologies is helping in the epidemiology of health complications like cancer. The growing prevalence of cancer worldwide, and proliferating health consciousness among people are factors set to drive the growth of the Cancer Biomarkers Industry for the period 2022-2027.
Report Coverage
The report: “Cancer Biomarkers Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Cancer Biomarkers Market.
By Biomolecule Type: Protein and Genetic Biomarkers.
By Cancer Type: Colorectal cancer, Lung Cancer, Prostate cancer, Breast Cancer, Stomach Cancer, Throat Cancer, and others.
By Application: Personalized/Modified medicine, Diagnosis, Novel Drug Research, and development.
By Technology: Bioinformatics and Cytogenetics, Imaging, Omics, and others.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).
Key Takeaways
For More Details on This Report - Request for Sample
Cancer Biomarkers Market Segment Analysis - By Application
The Cancer Biomarkers Market based on the application type can be further segmented into Personalized/Modified medicine, Diagnosis, Novel Drug Research, and development. The diagnosis and personalized medicines segment held the largest share in 2021. The growth is owing to augmenting the prevalence of cancer around the globe which has broadened peoples’ cognizance. Around 40-50% of cancers can be cured with ease if diagnosed at an early stage. Any sort of delay in diagnosis could be life-threatening and patients must bear the colossal cost of treatments. Moreover, this segment is estimated to be the fastest-growing segment with a CAGR of 12.4% over the forecast period 2022-2027. This growth is owing to the effectiveness of diagnostics techniques and personalized medicines in the treatment and recovery of patients. Personalized medicines aren’t part of hit-and-trial treatments. They are patient-specific therefore emphasize on prevention of disease. Moreover, they exempt a patient from the side effects of unnecessary treatments.
Cancer Biomarkers Market Segment Analysis - By Cancer Type
The Cancer Biomarkers Market based on cancer type can be further segmented into Colorectal Cancer, Lung Cancer, Prostate cancer, Breast Cancer, Stomach Cancer, Throat Cancer, and others. The breast cancer segment held the largest share in 2021. Breast cancer’s occurrence is more common than other forms such as prostate and stomach. Last year it claimed over 600,000 lives. Furthermore, it is more popular among the female population than men because female breast cells are always visible to estrogen and progesterone growth hormones. On another hand, frequent incidences of obesity in females have their fair share in the intensification of breast cancer cases. However, the magnitude of obesity prevalence varies from nation to nation. However, the lung cancer segment is estimated to be the fastest-growing segment with a CAGR of 12.7% over the forecast period 2022-2027. This growth is owing to an upsurge in trends of smoking and drinking alcohol among adults as well as teenagers. On another hand, worsening air quality in many countries like India, China, the US due to rapid industrialization and the growing automobile industry is another leading cause of lung cancer.
Cancer Biomarkers Market Segment Analysis - By Geography
The Cancer Biomarkers Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 41% of the overall market in 2021. The growth in this segment is owing to well-established healthcare infrastructure. The US and Canada are home to world-class research laboratories and hospitals such as Mayo clinic. Mayo Clinic was recently labeled as the world’s best hospital by a magazine Newsweek. Due to lower wait times, American cancer patients have higher survival rates than the rest of the world. Moreover, due to high salary offers the US always remains the first choice for professionals from around the world. Likewise, the high per capita income and living standards of Americans allow them to undergo various therapies and treatments. Furthermore, the US spends around $11,560 per person on Medi-care and has a healthcare budget of around $4 trillion which further stems from the R&D activities.
However, the Asia-Pacific segment is expected to offer lucrative growth opportunities to marketers. This growth is owing to the escalation in the number of geriatrics, innumerable flow of riches for the progress of healthcare facilities. Besides, the pollution situation in Asian nations like India, China, Pakistan is worsening day after day. Several Indian and Chinese cities have the worst air quality which is another leading cause of cancer prevalence.
Cancer Biomarkers Market Drivers
Soaring cancer cases worldwide is Anticipated to Boost Product Demand
The widespread prevalence of cancer is a major driver for the aforementioned market. According to a World Health Organization report, after heart problems, cancer is the biggest reason for deaths around the globe. Last year it claimed more than 10 million lives. Ascribing to an upsurge in smoking trends, pollution levels, poor ingestion habits the cancer is prevailing at high speed. In 2021 around 235,760 lung cancer cases were reported in the US. Moreover, every year over 130,000 people lose their lives due to lung cancer in the US. Not just in the US, its spread has been augmented in other parts of the world as the smoking percentage has reached around 19% worldwide.
Augmenting healthcare spending and disposable income of people is Expected to Boost Product Demand
Growing healthcare spending can be a big driver in the growth of the cancer biomarker market. Considering the soaring prevalence of health complications and virus attacks governments have started enlarging flows of hard cash in research work and other developments. For instance, currently, the US spends around 16% of GDP on the healthcare sector and the number is anticipated to surge in foreseeable future. Besides, with sky-rocketing exports of many developing countries, their GDP per capita income is also elevating. With a 10% hike, Bangladesh’s per capita income touched $2,227 in the financial year 2020-21. Therefore, with the expansion in disposable income, it becomes easy for people to spend on healthcare.
Cancer Biomarkers Market Challenges
The exorbitant cost of cancer diagnostic and treatment is Anticipated to Hamper Market Growth
Cancer treatments can cost a fortune which is the biggest challenge in front of cancer biomarkers. With growing success rates of cancer drugs, their prices are elevating also. The cost of cancer medications on monthly basis may cross $100,000 which the majority of the population can not afford to pay. Forget about poor and middle-class people even the rich struggles to fund the expenses of such extortionate treatments. The cost of medications can be 10-12 times what many people earn in a month. Consequently, it poses a serious setback in the growth of the respective market.
Cancer Biomarkers Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Cancer Biomarkers Market. Key companies of this market are-
Abbott Laboratories
Biomerieux
Thermo Fisher Scientific
Quest Diagnostics
Dickinson and Company
Roche Diagnostics
Agilent Technologies
Illumina
Qiagen
Affymetrix Inc.
Recent Developments
In January 2022, the University of Oxford has published in Clinical Cancer Research that a new type of blood test can be used to detect a range of cancers and whether these cancers have evenly spread throughout the body. The study had a sample size of 300 patients, with non-specific but concerning symptoms of cancer such as fatigue and weight loss. The following were recruited through the Oxfordshire Suspected Cancer Pathway. Results show that cancer was correctly detected in 19 out of every 20 patients with cancer using this test. In those with cancer, metastatic disease was identified with an overall accuracy of 94%.
In January 2022, Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. (“TTS”) to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”).
In January 2022, Nucleix has announced advancements in the early lung cancer detection program. Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced recent advances in its EpiCheck® Next Generation Sequencing (NGS) platform and lung cancer detection program for early-stage disease. The company also recently secured an additional $22 million in funding, as an extension to the previously announced $55 million financings, bringing the total capital raised in 2021 to $77 million, to rapidly advance the next generation of its highly sensitive lung cancer product and drive a multi-center prospective trial for clinical validation.
0 notes
Link
The global Cancer Biomarkers market size is expected to be worth around US$ 32.9 billion by 2030, according to a new report by Nova one advisor.
The global Cancer Biomarkers market size was valued at US$ 12.4 billion in 2022 and is anticipated to grow at a CAGR of 19.7% during forecast period 2022 to 2030.
0 notes
Text
Global Cancer Biomarkers Market size to surpass around USD 63.6 billion by 2031 | F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands)
The global cancer biomarkers market size was USD 13.4 billion in 2021 and it is anticipated to reach USD 63.6 billion by 2031, growing at a CAGR of 16.9% from 2022-2031.
Global Global Cancer Biomarkers Market report from Global Insight Services is the single authoritative source of intelligence on Global Cancer Biomarkers Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters’ and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.
Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body, estimated by collecting samples such as stool, tumor tissue, blood, urine, or other tissues or bodily fluids. Biomarkers may be formed by the cancer tissue itself or by other cells in the body in response to cancer. They enhance cancer detection and assist in high-speed noninvasive diagnosis using genomics and proteomics.
Get Access to A Free Sample Copy of Our Latest Report – https://www.globalinsightservices.com/request-sample/GIS10251/
Market Trends and Drivers
The key factor boosting the growth of the market is rising technological advancements in the development of cancer biomarkers. The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to great extent.
Similarly, the growing preference for personalized medicine is also boosting the growth of the market. Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases.
Global Cancer Biomarkers Market Segmentation
By Biomarker Type
Protein Biomarker
Genetic Biomarke
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassays
By Application
Diagnostics
Research & Development
Prognostics
By Region
North AmericaThe U.S.
Get A Customized Scope to Match Your Need Ask an Expert – https://www.globalinsightservices.com/request-customization/GIS10251/
Key Players
F. Hoffmann-La Roche Ltd. (Switzerland)
Thermo Fisher Scientific, Inc. (US)
QIAGEN N.V. (Netherlands)
Illumina, Inc. (US)
Bio-Rad Laboratories, Inc. (US)
Abbott Laboratories (US)
bioMérieux SA (US)
Becton, Dickinson and Company (US)
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Excel data pack included with all report purchases
Robust and transparent research methodology
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700
0 notes
Text
Cancer Biomarkers Market Growth Factors, Regional Overview, Competitive Strategies and Forecast Up To 2030
According to the deep-dive market assessment study conducted by Growth + Reports, the global Cancer Biomarkers market was pegged at ~ US$ 42.5 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030.
Biomarkers test also known as liquid biopsy test for cancer helps select the best suitable cancer treatment for patients. Biomarkers are used to monitor & predict cancer status in individuals or across populations so that appropriate therapeutic intervention can be planned. Rising incidence of various types of cancers, increasing R&D activities, growing initiatives for biomarker research, increasing applications of biomarkers in cancer diagnostics and drug discovery, and the rising trend of personalized medicine are some of the pivotal factors propelling the growth of the cancer biomarkers market. However, the high cost involved in biomarker validation, inconsistency in its performance in precise disease diagnosis, and validating biomarkers is a time consuming and costly process, thus holding market growth to a certain extent.
To access the Sample PDF of this research study, please request here: https://growthplusreports.com/inquiry/request-sample/cancer-biomarkers-market/7712
Personalized medicine involves using an individual's genetic profile to guide decisions made in regard to the diagnosis, prevention, and treatment of diseases. Advancements in biomarkers and personalized medicine have transformed the treatment of cancer, which has led to the development of innovative targeted immunotherapies and personalized treatment plans for patients. This had raised the demand for customized cancer treatments, which in turn is expected to propel the growth of the cancer biomarkers market. The prominent market players are progressively implementing several initiatives such as training programs to educate clinicians, pathologists, and patients about biomarkers.
Reports Segmentation: -
By Type:
· Genomic Biomarkers
· Proteomic Biomarkers
By Applications:
· Diagnostics
· Drug Discovery & Development
Some of the prominent players operating in the Cancer Biomarkers Market includes: -
· Qiagen NV
· F. Hoffmann-La Roche Ltd
· Thermo Fisher Scientific Inc
· General Electric Company
· Abbott Laboratories Inc
· Agilent Technologies, Inc
· Bio-Rad Laboratories, Inc
· Illumina, Inc
· bioMérieux SA
· Myriad Genetics, Inc
· Among others
Browse the full report now: https://growthplusreports.com/report/cancer-biomarkers-market/7712
About Us:
Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
0 notes
Last Seen Blogs
bigfestcloud-blog
Untitled
sentimentalcelestine
Nubivagant
dealsee
Dealsee Asia
lagartaenflor
lagarta ajena
mentalhealthmommy
Mental Health Mommy